Vitamin D and Pancreatic Cancer

Annals of Epidemiology

Volumn 19, Issue 2, 2009, Pages 89-95

  Stolzenberg Solomon, Rachael Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

25 Hydroxy Vitamin D Status; Pancreatic Cancer; Vitamin D Intake

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; BETA CAROTENE; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; MARGARINE; VITAMIN D;

CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; DEMOGRAPHY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; ECOLOGY; EXPERIMENTAL STUDY; FINLAND; FISH; HEALTH STATUS; HUMAN; NONHUMAN; NORTH AMERICA; PANCREAS CANCER; PANCREAS ISLET; PANCREAS ISLET CELL; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; SEASONAL VARIATION; SUN EXPOSURE; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

HUMANS; MALE; PANCREATIC NEOPLASMS; VITAMIN D;

EID: 58949095954     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2008.03.010     Document Type: Review

References (66)

1. Howe H.L., Wu X., Ries L.A., Cokkinides V., Ahmed F., Jemal A., et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107 (2006) 1711-1742
2. Anderson K.E., Mack T.M., and Silverman D. Pancreatic cancer. In: Schottenfeld D., and Fraumeni J.F. (Eds). Cancer Epidemiology and Prevention (2006), Oxford University Press, New York
3. Sahmoun A.E., D'Agostino Jr. R.A., Bell R.A., and Schwenke D.C. International variation in pancreatic cancer mortality for the period 1955-1998. Eur J Epidemiol 18 (2003) 801-816
4. Lowenfels A.B., Maisonneuve P., and Lankisch P.G. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am 28 (1999) 673-685 x
5. Berrington A., Sweetland S., and Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 89 (2003) 519-523
6. Larsson S.C., Orsini N., and Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 120 (2007) 1993-1998
7. Holick M.F., and Vitamin D. importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79 (2004) 362-371
8. Zittermann A. Vitamin D in preventive medicine: Are we ignoring the evidence?. Br J Nutr 89 (2003) 552-572
9. *stat (2007)
10. Schwartz G.G., and Blot W.J. Vitamin D status and cancer incidence and mortality: something new under the sun. J Natl Cancer Inst 98 (2006) 428-430
11. Grant W.B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer 120 (2007) 1123-1128
12. Boscoe F.P., and Schymura M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 6 (2006) 264
13. Mizoue T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys 87 (2004) 532-538
14. Kinoshita S., Wagatsuma Y., and Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int J Health Geogr 6 (2007) 34
15. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94 (2002) 1867-1875
16. Guyton K.Z., Kensler T.W., and Posner G.H. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev 61 (2003) 227-238
17. Whiting S.J., and Calvo M.S. Vitamin D and cancer symposium: Dietary recommendations to meet both endocrine and autocrine needs of Vitamin D. J Steroid Biochem Mol Biol 97 (2005) 7-12
18. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 89-90 (2004) 121-125
19. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86 (2001) 888-894
20. Schwartz G.G., Eads D., Rao A., Cramer S.D., Willingham M.C., Chen T.C., et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25 (2004) 1015-1026
21. Zugmaier G., Jager R., Grage B., Gottardis M.M., Havemann K., and Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 73 (1996) 1341-1346
22. Pettersson F., Colston K.W., and Dalgleish A.G. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer 83 (2000) 239-245
23. Ohlsson B., Albrechtsson E., Axelson J., and Vitamins A. D but not E and K decreased the cell number in human pancreatic cancer cell lines. Scand J Gastroenterol 39 (2004) 882-885
24. Colston K.W., James S.Y., Ofori-Kuragu E.A., Binderup L., and Grant A.G. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76 (1997) 1017-1020
25. Mouratidis P.X., Dalgleish A.G., and Colston K.W. Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells. Pancreas 32 (2006) 93-100
26. Kawa S., Yoshizawa K., Tokoo M., Imai H., Oguchi H., Kiyosawa K., et al. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110 (1996) 1605-1613
27. Mathieu C., Gysemans C., Giulietti A., and Bouillon R. Vitamin D and diabetes. Diabetologia 48 (2005) 1247-1257
28. Maestro B., Campion J., Davila N., and Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47 (2000) 383-391
29. Maestro B., Molero S., Bajo S., Davila N., and Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct 20 (2002) 227-232
30. Maestro B., Davila N., Carranza M.C., and Calle C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 84 (2003) 223-230
31. Hennig R., Ding X.Z., and Adrian T.E. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 19 (2004) 999-1011
32. Wang F., Herrington M., Larsson J., and Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer 2 (2003) 4
33. Bell Jr. R.H., McCullough P.J., and Pour P.M. Influence of diabetes on susceptibility to experimental pancreatic cancer. Am J Surg 155 (1988) 159-164
34. Pour P.M., Kazakoff K., and Carlson K. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin. Cancer Res 50 (1990) 1634-1639
35. Pour P.M., and Stepan K. Modification of pancreatic carcinogenesis in the hamster model. VIII. Inhibitory effect of exogenous insulin. J Natl Cancer Inst 72 (1984) 1205-1208
36. Zendehdel K., Nyren O., Ostenson C.G., Adami H.O., Ekbom A., and Ye W. Cancer incidence in patients with type 1 diabetes mellitus: A population-based cohort study in Sweden. J Natl Cancer Inst 95 (2003) 1797-1800
37. Hjalgrim H., Frisch M., Ekbom A., Kyvik K.O., Melbye M., and Green A. Cancer and diabetes-a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 241 (1997) 471-475
38. Schneider M.B., Matsuzaki H., Haorah J., Ulrich A., Standop J., Ding X.Z., et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120 (2001) 1263-1270
39. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., and Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2005) 194-202
40. Gapstur S.M., Gann P.H., Lowe W., Liu K., Colangelo L., and Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283 (2000) 2552-2558
41. Batty G.D., Shipley M.J., Marmot M., and Smith G.D. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: Findings from the original Whitehall study. Cancer Causes Control 15 (2004) 873-881
42. Balkau B., Barrett-Connor E., Eschwege E., Richard J.L., Claude J.R., and Ducimetiere P. Diabetes and pancreatic carcinoma. Diabete Metab 19 (1993) 458-462
43. Stolzenberg-Solomon R.Z., Graubard B.I., Chari S., Limburg P., Taylor P.R., Virtamo J., et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294 (2005) 2872-2878
44. Huxley R., Ansary-Moghaddam A., Barzi F., Berrington D.G., and Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 92 (2005) 2076-2083
45. Stattin P., Bjor O., Ferrari P., Lukanova A., Lenner P., Lindahl B., et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30 (2007) 561-567
46. Michaud D.S., Wolpin B., Giovannucci E., Liu S., Cochrane B., Manson J.E., et al. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16 (2007) 2101-2109
47. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98 (2006) 451-459
48. Platz E.A., Leitzmann M.F., Hollis B.W., Willett W.C., and Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15 (2004) 255-265
49. Platz E.A., Rimm E.B., Willett W.C., Kantoff P.W., and Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 92 (2000) 2009-2017
50. Skinner H.G., Michaud D.S., Giovannucci E., Willett W.C., Colditz G.A., and Fuchs C.S. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 15 (2006) 1688-1695
51. Weaver C.M., and Fleet J.C. Vitamin D requirements: Current and future. Am J Clin Nutr 80 6 Suppl (2004) 1735S-1739S
52. Stolzenberg-Solomon R.Z., Vieth R., Azad A., Pietinen P., Taylor P.R., Virtamo J., et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 66 (2006) 10213-10219
53. Hoppin J.A., Tolbert P.E., Holly E.A., Brock J.W., Korrick S.A., Altshul L.M., et al. Pancreatic cancer and serum organochlorine levels. Cancer Epidemiol Biomarkers Prev 9 (2000) 199-205
54. Porta M., Malats N., Jariod M., Grimalt J.O., Rifa J., Carrato A., et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 354 (1999) 2125-2129
55. Kiviranta H., Tuomisto J.T., Tuomisto J., Tukiainen E., and Vartiainen T. Polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in the general population in Finland. Chemosphere 60 (2005) 854-869
56. Risch H.A. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95 (2003) 948-960
57. Stolzenberg-Solomon R.Z., Pietinen P., Taylor P.R., Virtamo J., and Albanes D. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 155 (2002) 783-792
58. Calvo M.S., and Whiting S.J. Prevalence of vitamin D insufficiency in Canada and the United States: Importance to health status and efficacy of current food fortification and dietary supplement use. Nutr Rev 61 (2003) 107-113
59. Tuohimaa P., Tenkanen L., Ahonen M., Lumme S., Jellum E., Hallmans G., et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108 (2004) 104-108
60. Wu K., Feskanich D., Fuchs C.S., Willett W.C., Hollis B.W., and Giovannucci E.L. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99 (2007) 1120-1129
61. Holick M.F. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 120 Suppl. 11 (1990) 1464-1469
62. Carter G.D., Carter C.R., Gunter E., Jones J., Jones G., Makin H.L., et al. Measurement of Vitamin D metabolites: An international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 89-90 (2004) 467-471
63. Carter G.D., Carter R., Jones J., and Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50 (2004) 2195-2197
64. Freedman D.M., Looker A.C., Chang S.C., and Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99 (2007) 1594-1602
65. Tangrea J., Helzlsouer K., Pietinen P., Taylor P., Hollis B., Virtamo J., et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 8 4 (1997) 615-625
66. Giovannucci E. The epidemiology of vitamin D and colorectal cancer: Recent findings. Curr Opin Gastroenterol 22 (2006) 24-29